Current and Resolved Drug Shortages and Discontinuations Reported to FDA
Report a Drug Shortage |
Contact Us |
FAQ |
Background Info |
Get Email Alerts |
Download Current Drug Shortages
Start Over | Back to Previous Screen
Carboplatin Injection
Status: Currently in Shortage
»Date first posted:
04/28/2023
»Therapeutic Categories: Oncology
Accord Healthcare, Inc. (Revised 05/19/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 10 mg/mL; 45 mL Vial (NDC 16729-295-34) | Limited Availability | Marketed by Accord Healthcare. Current inventory is being allocated, further availability pending return to manufacturing | Other |
| 10 mg/mL; 60 mL Vial (NDC 16729-295-12) | Limited Availability | Marketed by Accord Healthcare. Current inventory is being allocated, further availability pending return to manufacturing | Other |
AuroMedics Pharma LLC (New 04/28/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 450 mg/45mL, MDV (NDC 55150-335-01) | Availability: Early May 2023 | Demand increase | |
| 600 mg/60mL, MDV (NDC 55150-386-01) | Availability: Early May 2023 | Demand increase |
Fresenius Kabi USA, LLC (Reverified 05/31/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 600 mg per 60 mL (10 mg per mL), multiple dose vial, (NDC 63323-172-60) | Backordered. Next release June 2023. | Demand increase |
Hospira, Inc., a Pfizer company (Revised 05/31/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 50 mg/5 mL (10 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial (NDC 61703-0339-18) | Next delivery: August 2023; Estimated recovery: December 2023 | Demand increase | |
| 50 mg/5 mL (10 mg/mL) Novaplus® Multiple Dose Vial (NDC 61703-0360-18) | Next delivery: July 2023; Estimated recovery: December 2023 | Demand increase | |
| 150 mg/15 mL (10 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial (NDC 61703-0339-22) | Next delivery: September 2023; Estimated recovery: December 2023 | Demand increase | |
| 150 mg/15 mL (10 mg/mL) Novaplus® Multiple Dose Vial (NDC 61703-0150-05) | Next delivery: September 2023; Estimated recovery: December 2023 | Demand increase | |
| 450 mg/45 mL (10 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial (NDC 61703-0339-50) | Limited Supply. Next delivery: June 2023; Estimated recovery: December 2023 | Demand increase | |
| 450 mg/45 mL (10 mg/mL) Novaplus® Multiple Dose Vial (NDC 61703-0262-05) | Next delivery: June 2023; Estimated recovery: December 2023 | Demand increase | |
| 600 mg/60 mL (10 mg/mL) Multiple Dose ONCO-TAIN™ Glass Fliptop Vial (NDC 61703-0339-56) | Limited Supply. Next delivery: June 2023; Estimated recovery: December 2023 | Demand increase | |
| 600 mg/60 mL (10 mg/mL) Novaplus® Multiple Dose Vial (NDC 61703-0600-05) | Next delivery: June 2023; Estimated recovery: December 2023 | Demand increase |
Teva Pharmaceuticals (Reverified 05/23/2023)
| Presentation | Availability and Estimated Shortage Duration | Related Information | Shortage Reason (per FDASIA) |
|---|---|---|---|
| 50 mg/5 mL (10 mg/mL) 5 mL Multi-Dose Vial (NDC 0703-4244-01 ) | Limited Supply, Recovery Q4 2023 | Other | |
| 150 mg/15 mL (10 mg/mL) 15 mL Multi-Dose Vial (NDC 0703-4246-01) | Limited Supply, Recovery Q4 2023 | Other | |
| 450 mg/45 mL (10 mg/mL) 45 mL Multi-Dose Vial (NDC 0703-4248-01) | Allocating Available Supply; Recovery Q4 2023 | Other | |
| 600 mg/60 mL (10 mg/mL) 60 mL Multi-Dose Vial (NDC 0703-4239-01) | Allocating Available Supply; Recovery Q4 2023 | Other |